<a href="https://www.fiercebiotech.com/medtech/boehringer-hands-over-funding-commercialisation-rights-clicks-digital-therapeutic" hreflang="en">Boehringer hands over funding, marketing rights for Click’s digital therapeutic</a>
Boehringer Ingelheim and Click Therapeutics are revising their marketing agreement for the schizophrenia treatment CT-155, with Boehringer Ingelheim providing additional funding.
The key learning for you is that Boehringer Ingelheim's restructuring of its marketing deal with Click Therapeutics for the digital schizophrenia treatment CT-155 indicates a strategic pivot in how traditional pharmaceutical companies are investing in digital therapeutics. This move underscores the importance of partnerships and financial backing in scaling healthtech solutions, offering a potential opportunity to explore similar collaborations or investments in digital therapeutics that integrate software-based treatments with conventional pharmaceutical approaches.